Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'

doi:10.1016/j.jhep.2022.04.029

Comment

. 2022 Aug;77(2):567-568.

doi: 10.1016/j.jhep.2022.04.029. Epub 2022 May 5.

Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'

Roberto de Franchis¹, Jaume Bosch², Guadalupe Garcia-Tsao³, Thomas Reiberger⁴, Cristina Ripoll⁵

Affiliations

¹ Department of Biomedical and Clinical Sciences, University of Milan, Italy. Electronic address: roberto.defranchis@unimi.it.
² Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Instituts d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CIBERehd, University of Barcelona, Spain.
³ Yale University, New Haven, USA; VA-CT Healthcare System, West Haven, USA.
⁴ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
⁵ Internal Medicine IV, Universitätsklinikum Jena, Friedrich Schiller University, Jena, Germany.

PMID: 35526788
DOI: 10.1016/j.jhep.2022.04.029

Free article

Comment

Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'

Roberto de Franchis et al. J Hepatol. 2022 Aug.

Free article

. 2022 Aug;77(2):567-568.

doi: 10.1016/j.jhep.2022.04.029. Epub 2022 May 5.

Authors

Roberto de Franchis¹, Jaume Bosch², Guadalupe Garcia-Tsao³, Thomas Reiberger⁴, Cristina Ripoll⁵

Affiliations

¹ Department of Biomedical and Clinical Sciences, University of Milan, Italy. Electronic address: roberto.defranchis@unimi.it.
² Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Instituts d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CIBERehd, University of Barcelona, Spain.
³ Yale University, New Haven, USA; VA-CT Healthcare System, West Haven, USA.
⁴ Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
⁵ Internal Medicine IV, Universitätsklinikum Jena, Friedrich Schiller University, Jena, Germany.

PMID: 35526788
DOI: 10.1016/j.jhep.2022.04.029

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment on

Baveno VII - Renewing consensus in portal hypertension.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. de Franchis R, et al. J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30. J Hepatol. 2022. PMID: 35120736 Free PMC article. Review.
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma.
Ollivier-Hourmand I, Allaire M, Cervoni JP; Club Francophone pour l’Etude de l’Hypertension Portale. Ollivier-Hourmand I, et al. J Hepatol. 2022 Aug;77(2):566-567. doi: 10.1016/j.jhep.2022.02.004. Epub 2022 Feb 17. J Hepatol. 2022. PMID: 35182660 No abstract available.

Cited by

Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion.
Balcar L, Mrekva A, Scheiner B, Pomej K, Meischl T, Mandorfer M, Reiberger T, Trauner M, Tamandl D, Pinter M. Balcar L, et al. Cancer Imaging. 2024 Jan 13;24(1):9. doi: 10.1186/s40644-024-00657-z. Cancer Imaging. 2024. PMID: 38217049 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'

Affiliations

Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical